Semax Research Overview
Semax is studied as an ACTH(4-7)-derived synthetic peptide with a Pro-Gly-Pro extension. Its experimental literature includes region-specific neurotrophin gene expression and transcriptional changes after cerebral-ischemia models. Those findings are mechanistic research observations, not evidence for a commercial “nootropic” effect.
Semax is not ACTH
The common ACTH(4-7)PGP description identifies a structural relationship to an ACTH fragment. Semax is not full-length ACTH, and evidence for ACTH itself should not automatically be assigned to Semax. Likewise, a PGP-containing fragment can have its own experimental behaviour and should be named precisely.
Neurotrophin gene expression is region-specific
In normal rat brain, Semax exposure produced rapid, region-specific changes in Bdnf and Ngf expression. Some regions showed increases while others showed decreases. PubMed.
That pattern is more informative than the slogan “Semax increases BDNF”. A whole-brain or clinical inference would discard the regional heterogeneity reported in the experiment.
Ischaemia-model transcription research
In rat cerebral-ischaemia work, Semax and PGP-related material have been associated with changes in neurotrophin/receptor transcription. PubMed. More recent transcriptomic research has also reported changes in inflammation-related gene expression in an experimental cerebral-ischaemia context. PubMed.
These studies examine molecular responses after defined experimental injury. They do not establish a clinical neuroprotective effect, cognitive enhancement or a safe human-use protocol.
How to interpret Semax evidence
| Evidence detail | Interpretive limit |
|---|---|
| Brain-region gene expression | A change in one region should not be generalised to the whole brain. |
| Neurotrophin/receptor transcripts | Transcriptional change is not equivalent to a behavioural or clinical outcome. |
| Cerebral-ischaemia models | Experimental injury models do not establish treatment efficacy in people. |
| PGP fragment comparisons | Related fragments should be reported as the exact tested material. |
Relationship to Selank
Semax and Selank are distinct synthetic peptide families. Their PGP-related descriptions do not make them interchangeable. The Selank research overview covers its separate gene-expression evidence.
Identity and batch documentation
Exact sequence, terminal form, salt/counter-ion, mass, chromatographic result and lot identity should be confirmed from the applicable product documentation. A literature description of ACTH(4-7)PGP does not authenticate the contents of a commercial vial.
Use Batch Documentation, the HPLC guide and the mass-spectrometry guide for the analytical evidence layer.
Catalogue formats
Core Research lists Semax 10mg and Semax Refill 10mg. The refill is a separate finished presentation and requires its own cartridge/format evidence.
Research-use boundary
Core Research Semax products are supplied for laboratory research use only, not for human or veterinary use. No cognitive-enhancement, neuroprotection, dosing or administration guidance is provided.
Selected references
- Semax effects on BDNF and NGF gene expression in rat brain. PMID 17353092.
- Semax/PGP effects on neurotrophin-related expression after cerebral ischaemia. PMID 19633950.
- Semax-related changes in inflammatory gene expression after experimental cerebral ischaemia. PMID 34097675.